NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 247 filers reported holding NEKTAR THERAPEUTICS in Q4 2021. The put-call ratio across all filers is 0.92 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $4,274,000 | +4.9% | 237,988 | +0.2% | 0.02% | +6.7% |
| Q2 2021 | $4,076,000 | -14.3% | 237,506 | -0.1% | 0.02% | -16.7% |
| Q1 2021 | $4,756,000 | +19.6% | 237,789 | +1.7% | 0.02% | +12.5% |
| Q4 2020 | $3,975,000 | +2.6% | 233,840 | +0.1% | 0.02% | -11.1% |
| Q3 2020 | $3,875,000 | -28.0% | 233,562 | +0.6% | 0.02% | -30.8% |
| Q2 2020 | $5,379,000 | +31.5% | 232,254 | +1.4% | 0.03% | +13.0% |
| Q1 2020 | $4,089,000 | -17.3% | 229,079 | 0.0% | 0.02% | +4.5% |
| Q4 2019 | $4,945,000 | -30.9% | 229,079 | -41.7% | 0.02% | -35.3% |
| Q3 2019 | $7,154,000 | +147.4% | 392,772 | +383.2% | 0.03% | +142.9% |
| Q2 2019 | $2,892,000 | -61.3% | 81,289 | -63.5% | 0.01% | -61.1% |
| Q1 2019 | $7,478,000 | +0.2% | 222,568 | -1.9% | 0.04% | -12.2% |
| Q4 2018 | $7,460,000 | -31.3% | 226,947 | +27.4% | 0.04% | -19.6% |
| Q3 2018 | $10,856,000 | +53.8% | 178,088 | +23.2% | 0.05% | +45.7% |
| Q2 2018 | $7,057,000 | -13.6% | 144,526 | +88.0% | 0.04% | -12.5% |
| Q1 2018 | $8,169,000 | – | 76,877 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Monaco Asset Management SAM | 4,809,601 | $2,864,598 | 0.85% |
| Lynx1 Capital Management LP | 1,766,815 | $1,052,315 | 0.70% |
| CM Management, LLC | 800,000 | $476,480 | 0.51% |
| Deep Track Capital, LP | 18,400,000 | $10,959,040 | 0.42% |
| TANG CAPITAL MANAGEMENT LLC | 3,939,600 | $2,346,426 | 0.33% |
| Acuitas Investments, LLC | 721,460 | $429,702 | 0.25% |
| RA Capital Management | 18,700,000 | $11,137,720 | 0.22% |
| GSA CAPITAL PARTNERS LLP | 1,841,078 | $1,097 | 0.09% |
| UBS OCONNOR LLC | 1,376,249 | $820,244 | 0.02% |
| Marquette Asset Management, LLC | 148,378 | $88,374 | 0.02% |